医学
醋酸甲孕酮
激素疗法
更年期
雌激素
子宫切除术
妇女健康倡议
激素替代疗法(女性对男性)
安慰剂
卵巢切除术
随机对照试验
人口
孕激素
内科学
妇科
乳腺癌
外科
绝经后妇女
癌症
替代医学
睾酮(贴片)
病理
环境卫生
作者
JoAnn E. Manson,Shari S. Bassuk,Andrew M. Kaunitz,JoAnn V. Pinkerton
出处
期刊:Menopause
[Lippincott Williams & Wilkins]
日期:2020-04-27
卷期号:27 (8): 918-928
被引量:43
标识
DOI:10.1097/gme.0000000000001553
摘要
Abstract Objective: The Women's Health Initiative (WHI) assessed oral conjugated equine estrogens (CEE) taken with or without medroxyprogesterone acetate (MPA) for prevention of chronic disease in postmenopausal women aged 50-79 years. Methods: Women with an intact uterus ( n = 16,608) were randomized to CEE+ MPA therapy or placebo for a median of 5.6 years; women with hysterectomy ( n = 10,739) were randomized to CEE-alone therapy or placebo for a median of 7.2 years. Both cohorts have been followed for 18 years. Results: In the overall study population (mean age, 63 y), neither estrogen-progestin therapy (EPT) nor estrogen-only therapy prevented coronary heart disease or led to a favorable balance of chronic-disease benefits and risks. Subgroup analyses, however, suggest that timing of hormone therapy (HT) initiation influences the relation between HT and coronary risk, as well as its overall benefit-risk balance, with more favorable effects in women who are younger (age < 60 year) or recently menopausal (within 10 year) than in women who are older or further past the menopausal transition. In younger women who entered the trial of estrogen-only therapy with oophorectomy, the intervention was associated with a significant 32% reduction in all-cause mortality over long-term follow-up. Conclusions: WHI findings indicate important differences in HT-related clinical outcomes by age and time since menopause. Systemic HT has an acceptable safety profile for menopause management when initiated among healthy women who are younger (or recently menopausal) and not at elevated risk for cardiovascular disease or breast cancer. Initiation of treatment in older women who are distant from menopause onset, however, should be avoided. Other HT formulations and routes of delivery warrant further study. (WHI clinicaltrials.gov identifier: NCT00000611)
科研通智能强力驱动
Strongly Powered by AbleSci AI